and have a life expectancy of 1 year. Patients who are 
in cytogenetic or hematological remissions following 
induction of second chronic phase, following blast crisis 
or accelerated phase, are eligible for this study. 
4.2 Patients should be off all interferon therapy for four 
weeks prior to autologous storage. Prior treatment does 
not disqualify a patient from eligibility. 
4.3 Patients must have a performance <3 on Zubrod scale 
(Appendix A), a creatinine level less than 1.6 mg%, 
acceptable cardiac condition (class I or II; Appendix 2), 
normal liver functions with bilirubin less than 2 mg%, 
and acceptable pulmonary condition (FEV and DLCO >50% of 
predicted) . Patients should be free of infections at the 
time of treatment. Patients should have a LVEF >50%. 
4.4 A serum creatinine less than 1.6 and an SGOT within the 
normal range is required. 
4.5 Patients in second chronic phase or cytogenetic remission 
following reinduction c?f chronic phase after blastic 
crisis or accelerated phase must have an autologous bone 
marrow stored with 30% of the cells exposed to the LNL6 
retrovirus, and peripheral blood exposed to the GINa 
virus. Patients must sign informed consent, must not be 
pregnant or lactating, and must be practicing adequate 
contraception if of childbearing potential. 
4.6 No patient who is unresponsive to platelet infusions will 
be eligible for this study. 
5 . 0 TREATMENT PLAN 
5.1 General: All patients should be registered with the data 
management office, Ext: 2-2926. Information pertaining 
to important patient characteristics will be recorded. 
5.2 Bone marrow aspiration and collection of peripheral blood 
stem cells and storage: Peripheral blood and marrow is 
to be stored whether they are in cytogenetic remission or 
in second chronic phase. In vitro methods (CD34 
selection) for reducing Ph+ cells as well as in vivo 
(daunomycin, high dose ara-c, GMCSF or other equivalent 
chemotherapy) methods for reducing Ph+ cells will be used 
to reduce the level of Ph+ blast cells in the population 
of autologous marrow cells to be used for transplant. 
Purged (CD34 selected) peripheral blood and marrow cells 
which have been collected following reinduction of second 
chronic phase or induction of cytogenetic remissions 
following treatment of accelerated phase or blastic 
crisis with conventional dose chemotherapy (daunomycin, 
high dose ara-c, GMCSF, or other equivalent 
chemotherapy) , will be used for restoration of marrow 
Recombinant DNA Research, Volume 15 
[865] 
